問卷

TPIDB > 臨床試驗主持人

臨床試驗主持人



更新時間:2023-09-19

毛衛中
  • 計畫主持人
  • 執行臨床試驗年資

篩選

搜尋計畫列表

8

2003-11-01 -

Phase III

尚未開始召募
  • 適應症

    Mechanism: Sertindole as a antipsychotic drugs , is derived from its selective inhibitory effect on mesolimbic dopaminergic neurons and is due to balanced inhibitory effects on central dopamine D2 and serotonin 5HT2 receptors as on a1-adrengic receptors. Indications: schizophrenia. Due to cardiovascular safety concerns, sertindole should only be used for patients intolerant to at least one other antipsychotic agent. Sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients

  • 藥品名稱

參與醫院
3

召募中3

2009-06-01 - 2012-12-31

Phase III

隨機分配、雙盲、安慰劑對照研究,評估Paliperidone Palmitate作為Lithium或Valproate的輔助療法,用於預防第一型躁鬱症復發型情緒症狀
  • 適應症

    第一型躁鬱症復發型

  • 藥品名稱

    Paliperidone Palmitate

參與醫院
3

終止收納3

2008-04-01 - 2008-10-31

Phase III

A randomized, double blind, active-controlled and parallel study to evaluate the efficacy and safety of zaleplon compared with zolpidem in adult outpatients with insomnia.
  • 適應症

    失眠

  • 藥品名稱

    學名:Zaleplon/商品名:Sonimax

參與醫院
5

終止收納5